Singapore markets close in 6 hours 44 minutes
  • Straits Times Index

    3,216.23
    -1.94 (-0.06%)
     
  • Nikkei

    28,841.21
    -257.03 (-0.88%)
     
  • Hang Seng

    25,636.25
    +7.51 (+0.03%)
     
  • FTSE 100

    7,253.27
    -24.35 (-0.33%)
     
  • BTC-USD

    58,822.39
    -1,806.23 (-2.98%)
     
  • CMC Crypto 200

    1,409.39
    -64.94 (-4.41%)
     
  • S&P 500

    4,551.68
    -23.11 (-0.51%)
     
  • Dow

    35,490.69
    -266.19 (-0.74%)
     
  • Nasdaq

    15,235.84
    +0.12 (+0.00%)
     
  • Gold

    1,800.90
    +2.10 (+0.12%)
     
  • Crude Oil

    81.01
    -1.65 (-2.00%)
     
  • 10-Yr Bond

    1.5290
    -0.0900 (-5.56%)
     
  • FTSE Bursa Malaysia

    1,578.41
    -4.67 (-0.29%)
     
  • Jakarta Composite Index

    6,568.81
    -33.40 (-0.51%)
     
  • PSE Index

    7,191.35
    -38.80 (-0.54%)
     

ARDX Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Ardelyx, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: September 28, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, September 24, 2021--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Ardelyx securities between August 6, 2020 and July 19, 2021, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/ardx.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose material adverse facts including: (1) Ardelyx repeatedly lauded this development, highlighting the FDA's acceptance and review of the NDA, supported by so-called "successful" Phase 3 studies, in each subsequently filed quarterly report and in the Company's 2020 Annual Report; (2) the likelihood that tenapanor would be approved by the FDA; (3) defendants possessed, were in control over, and, as a result, knew (or had reason to know) that the data submitted to support the NDA was insufficient in that it showed a lack of clinical relevance of the drug's treatment effect, making it foreseeably likely (if not certain) that the FDA would not approve the drug.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/ardx or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC, at 212-697-6484. If you suffered a loss in Ardelyx you have until September 28, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210924005001/en/

Contacts

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting